Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome

APMIS

Volumn 125, Issue 3, 2017, Pages 259-263

  Ruiz Bañobre, Juan ^a   Abdulkader, Ihab ^b   Anido, Urbano ^a   León, Luis ^c   López López, Rafael ^a   García González, Jorge ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c SERGAS Complejo Hospitalario Universitario de Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CD3 ANTIBODY; CD4 ANTIBODY; CD8 ANTIBODY; DEXAMETHASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANGERIN; MONOCLONAL ANTIBODY; NIVOLUMAB; POLYMER; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; BONE METASTASIS; BRAIN METASTASIS; CANCER SURGERY; CASE REPORT; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; LETTER; LUNG METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; QUALITY OF LIFE; RADIOSURGERY; RASH; SKIN BIOPSY; X-RAY COMPUTED TOMOGRAPHY; BIOPSY; CHEMICALLY INDUCED; COMPLICATION; DRUG ERUPTION; KIDNEY TUMOR; LANGERHANS CELL; PATHOLOGY; PATHOPHYSIOLOGY; PSORIASIS; RENAL CELL CARCINOMA; SKIN; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BIOPSY; CARCINOMA, RENAL CELL; DRUG ERUPTIONS; HUMANS; KIDNEY NEOPLASMS; LANGERHANS CELLS; MALE; MIDDLE AGED; PSORIASIS; SKIN; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 85013854802     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12658     Document Type: Letter

References (18)

1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373: 1803–1813.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496–509.
3. Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol 2012;42: 2274–84.
4. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129:311–21.
5. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013;34:174–81.
6. Kim DS, Je JH, Kim SH, et al. Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis. Arch Dermatol Res 2015;307:531–8.
7. Peña-Cruz V, McDonough SM, Diaz-Griffero F, Crum CP, Carrasco RD, Freeman GJ. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol 2010;130: 2222–30.
8. Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of antibodies to programmed cell death 1 ligand 1. Arch Pathol Lab Med 2016;140:326–31.
9. Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016;29:1165–1172.
10. Sholl LM, Aisner DL, Allen TC, et al. Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists: a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 2016;140:341–4.
11. Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016;468:511–25.
12. Glitzner E, Korosec A, Brunner PM, et al. Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol Med 2014;6:1312–27.
13. Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 2015;30:e89–91.
14. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2015;17:259–60.
15. Murata S, Kaneko S, Harada Y, Aoi N, Morita E. Case of de novo psoriasis possibly triggered by nivolumab. J Dermatol 2016;44:99–100.
16. Corvellec H, Kato Y, Otsuka A, et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. Acta Derm Venereol 2015;17:1–2.
17. Sahuquillo-Torralba A, Ballester-Sánchez R, Pujol-Marco C, Botella-Estrada R. Pembrolizumab: a new drug that can induce exacerbations of psoriasis. Actas Dermosifiliogr 2016;107:264–6.
18. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015;151:1206–12.